WHO ICTRP trial
Clinical study on Cangma Huadu Granules treating mild COVID-19
ChiCTR2300070933 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300070933 |
|---|---|
| Public title | Clinical study on Cangma Huadu Granules treating mild COVID-19 |
| Scientific title | A multicenter, randomized, double-blind, parallel controlled study of Cangma Huadu Granules in the treatment of mild COVID-19 |
| Primary sponsor | Beijing Hospital of Traditional Chinese Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | COVID-19 |
| Interventions | Experimental group:Basic treatment + Cangma Huadu granules;Control group:Basic treatment + placebos |
| Registration date | Apr 26, 2023 |
| Target size | Experimental group:60;Control group:60 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: